Occupational exposure to HIV in health care settings

New England Journal of Medicine

Volumn 348, Issue 9, 2003, Pages 826-833

  Gerberding, Julie Louise ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; STAVUDINE; VIDEX EC; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ANOREXIA; CHEMOPROPHYLAXIS; DIARRHEA; DISEASE TRANSMISSION; DRUG HYPERSENSITIVITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HEALTH CARE PERSONNEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INFECTION RISK; INSOMNIA; LACTIC ACIDOSIS; LIVER TOXICITY; LYMPHOCYTE COUNT; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEEDLE; NEPHROLITHIASIS; NEUROPATHY; NEUTROPENIA; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; PANCREATITIS; PERIPHERAL NEUROPATHY; PHLEBOTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RASH; RETROSPECTIVE STUDY; REVIEW; RISK BENEFIT ANALYSIS; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SYRINGE; T LYMPHOCYTE SUBPOPULATION; UNITED STATES; VERTIGO; VIRUS LOAD; ADULT; BLOODBORNE BACTERIUM; CASE REPORT; NEEDLESTICK INJURY; OCCUPATIONAL ACCIDENT; PARAMEDICAL PERSONNEL;

ACCIDENTS, OCCUPATIONAL; ADULT; ALLIED HEALTH PERSONNEL; ANTI-HIV AGENTS; BLOOD-BORNE PATHOGENS; DISEASE TRANSMISSION, PATIENT-TO-PROFESSIONAL; HIV INFECTIONS; HUMANS; NEEDLESTICK INJURIES; OCCUPATIONAL EXPOSURE; PHLEBOTOMY; PRACTICE GUIDELINES;

EID: 0037468373     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMcp020892     Document Type: Review

References (38)

1. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Morb Mortal Wkly Rep 2001;50(RR-11):1-52.
2. NIOSH alert: preventing needlestick injuries in health care settings. Cincinnati: National Institute for Occupational Safety and Health, November 1999. (DHHS publication no. (NIOSH) 2000-108.)
3. HIV/AIDS surveillance report. Vol. 12. No. 1. Atlanta: Centers for Disease Control and Prevention, 2000:24.
4. Occupational safety: selected cost and benefit implications of needlestick prevention devices for hospitals. Washington, D.C.: General Accounting Office, November 17, 2000. (GAO-01-60R.)
5. Busch M, Lee LL, Satten GA, et al. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion 1995;35:91-7.
6. Salgado CD, Flanagan HL, Haverstick DM, Farr BM. Low rate of false-positive results with use of a rapid HIV test. Infect Control Hosp Epidemiol 2002;23:335-7.
7. Kallenborn JC, Price TG, Carrico R, Davidson AB. Emergency department management of occupational exposures: cost analysis of rapid HIV test. Infect Control Hosp Epidemiol 2001;22:289-93.
8. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV sero-conversion in health care workers after percutaneous exposure. N Engl J Med 1997;337:1485-90.
9. Böttiger D, Johansson N-G, Samuelsson B, et al. Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005. AIDS 1997;11:157-62.
10. Otten RA, Smith DK, Adams DR, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol 2000;74:9771-5.
11. Martin LN, Murphey-Corb M, Soike KF, Davison-Fairburn B, Baskin GB. Effects of initiation of 3′-azido,3′-deoxythymidine (zidovudine) treatment at different times after infection of rhesus monkeys with simian immunodeficiency virus. J Infect Dis 1993;168:825-35.
12. Tsai C-C, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9(2-phosphonylmethoxypropyl)adenine. Science 1995;270:1197-9.
13. Tsai C-C, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998;72:4265-73.
14. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States (revised November 3, 2000). HIV Clin Trials 2001;2:56-91.
15. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
16. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996;335:1621-9.
17. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998;339:1409-14.
18. Musoke P, Guay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999;13:479-86.
19. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354:795-802.
20. Jochimsen EM. Failures of zidovudine postexposure prophylaxis. Am J Med 1997;102:Suppl 5B:52-5.
21. Pratt RD, Shapiro JF, McKinney N, Kwok S, Spector SA. Virologic characterization of primary human immunodeficiency virus type 1 infection in a health care worker following needlestick injury. J Infect Dis 1995;172:851-4.
22. Lot F, Abiteboul D. Infections professionnelles par le VIH en France chez le personnel de santé e point au 30 Juin 1995. Bull Epidemiol Hebd 1995;44:193-4.
23. Weisburd G, Biglione J, Arbulu MM, Terrazzino JC, Pesiri A. HIV seroconversion after a work place accident and treated with zidovudine. In: Abstracts of the XI International Conference on AIDS, Vancouver, B.C., July 7-12, 1996:460. abstract.
24. Perdue B, Wolderufael D, Mellors J, Quinn T, Margolick J. HIV-1 transmission by a needlestick injury despite rapid initiation of four-drug postexposure prophylaxis. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31-February 4, 1999. Chicago: Foundation for Retrovirology and Human Health, 1999:107. abstract.
25. Beltrami EM, Luo C-C, Dela Torre N, Cardo DM. HIV transmission after an occupational exposure despite postexposure prophylaxis with a combination drug regimen. In: Program and abstracts of the 4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections: in conjunction with the 10th Annual Meeting of SHEA, Atlanta, March 5-9, 2000. Atlanta: Centers for Disease Control and Prevention, 2000:125-6. abstract.
26. Wang SA, Panlilio AL, Doi PA, White AD, Stek M Jr, Saah A. Experience of healthcare workers taking postexposure prophylaxis after occupational HIV exposures: findings of the HIV Postexposure Prophylaxis Registry. Infect Control Hosp Epidemiol 2000;21:780-5.
27. Struble KA, Pratt RD, Gitterman SR. Toxicity of antiretroviral agents. Am J Med 1997;102:Suppl 5B:65-7.
28. Trape M, Barnosky S. Nelfinavir in expanded postexposure prophylaxis causing acute hepatitis with cholestatic features: two case reports. Infect Control Hosp Epidemiol 2001;22:333-4.
29. Henry K, Acosta EP, Jochimsen E. Hepatotoxicity and rash associated with zidovudine and zalcitabine chemoprophylaxis. Ann Intern Med 1996;124:855.
30. Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers. JAMA 2000;284:2722-3.
31. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures - worldwide, 1997-2000. MMWR Morb Mortal Wkly Rep 2001;49:1153-6.
32. U.S. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Rockville, Md.: HIV/AIDS Clinical Trials Information Service, August 2002. (Accessed January 6, 2003, at http://www.aidsinfo.nih.gov/document/data/guidelines_html_lib/ perinatal.083002.html.)
33. Beltrami EM, Cheingsong R, Respess R, Cardo DM. Antiretroviral drug resistance in HIV-infected source patients for occupational exposures to healthcare workers. In: Program and abstracts of the 4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections: in conjunction with the 10th Annual Meeting of SHEA, Atlanta, March 5-9, 2000. Atlanta: Centers for Disease Control and Prevention, 2000:128. abstract.
34. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002;288:222-35.
35. Pinto LA, Landay AL, Berzofsky JA, Kessler HA, Shearer GM. Immune response to human immunodeficiency virus (HIV) in healthcare workers occupationally exposed to HIV-contaminated blood. Am J Med 1997;102:Suppl 5B:21-4.
36. Rich JD, Merriman NA, Mylonakis E, et al. Misdiagnosis of HIV infection by HIV-1 plasma viral load testing: a case series. Ann Intern Med 1999;130:37-9.
37. Roland ME, Elbeik TA, Martin JN, et al. HIV-1 RNA testing by bDNA and PCR in asymptomatic patients following sexual exposure to HIV. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30 - February 2, 2000. San Francisco: Foundation for Retrovirology and Human Health, 2000:220. abstract.
38. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Rockville, Md.: HIV/AIDS Clinical Trials Information Service, February 2002. (Accessed February 3, 2003, at http://www.aidsinfo.nih.gov/document/dataguidelines_html_lib/html_ adult_02-04-02.html.)